Inside the JCI Discovery: How GO-037 Helped Reveal a Pro-Tumor Secretory Program

A 2025 Journal of Clinical Investigation study by Ghosh et al. uncovers how the EGFR inhibitor osimertinib paradoxically activates a TGFβ2-dependent secretory program that accelerates lung adenocarcinoma progression. In this work, researchers leveraged Invent Biotechnologies’ GO-037 Golgi isolation kit to enrich Golgi-associated fractions efficiently, enabling precise analysis of drug-induced secretory pathway remodeling. The findings highlight the central role of Golgi-mediated protein trafficking in therapy resistance and underscore GO-037 as a powerful tool for dissecting secretory mechanisms in cancer biology.

Reference

Ghosh, M., Wu, C., Kumar, A., Nilsson, M. B., Heymach, J. V., Zhao, W., ... & Kurie, J. M. (2025). Osimertinib activates a TGFβ2-dependent secretory program that drives lung adenocarcinoma progression. The Journal of Clinical Investigation.